ID: ALA4764520

Max Phase: Preclinical

Molecular Formula: C16H13N5O

Molecular Weight: 291.31

Molecule Type: Unknown

Representations

Canonical SMILES:  Cn1ccc2cc(Nc3n[nH]c4cccnc34)ccc2c1=O

Standard InChI:  InChI=1S/C16H13N5O/c1-21-8-6-10-9-11(4-5-12(10)16(21)22)18-15-14-13(19-20-15)3-2-7-17-14/h2-9H,1H3,(H2,18,19,20)

Standard InChI Key:  GPSBNKMZVOTIBW-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 291.31

Molecular Weight (Monoisotopic): 291.1120

AlogP: 2.55

#Rotatable Bonds: 2

Polar Surface Area: 75.60

Molecular Species: NEUTRAL

HBA: 5

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.88

CX Basic pKa: 2.57

CX LogP: 2.07

CX LogD: 2.07

Aromatic Rings: 4

Heavy Atoms: 22

QED Weighted: 0.59

Np Likeness Score: -1.25

References

1. Panarese JD,Engers DW,Wu YJ,Guernon JM,Chun A,Gregro AR,Bender AM,Capstick RA,Wieting JM,Bronson JJ,Macor JE,Westphal R,Soars M,Engers JE,Felts AS,Rodriguez AL,Emmitte KA,Jones CK,Blobaum AL,Conn PJ,Niswender CM,Hopkins CR,Lindsley CW.  (2019)  The discovery of VU0652957 (VU2957, Valiglurax): SAR and DMPK challenges en route to an mGlu PAM development candidate.,  29  (2.0): [PMID:30503632] [10.1016/j.bmcl.2018.10.050]

Source

Source(1):

• Scientific Literature